spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Kloeckner Pentaplast Announces Plans for New Lamination Facility

Kloeckner Metals

A state-of-the-art system will be used to produce laminated pharmaceutical films

Montabaur, Germany – June 7, 2016 – The Klöckner Pentaplast Group announced plans today to expand its high-barrier film lamination and coating capacities to reinforce the company’s commitment to the global pharmaceutical and medical industries. Beginning in early 2017, Klöckner Pentaplast will use a state-of-the-art system to produce Aclar® laminated pharmaceutical films from its site in Montabaur, Germany, a trusted source of high quality kp films for many industries. The new Montabaur line will be fully operational for the entire kp Pentapharm® Aclar® product range by the end of 2017.

As a result of this investment, the Klöckner Pentaplast facility in Bern, Switzerland will also have added capacity available to produce PVdC-coated high-barrier pharmaceutical films, while continuing to be a backup site for Aclar® lamination. The plan strengthens kp’s dedication to its global packaging customers by providing improved customer service and security of supply from multiple sites under a global DMF.

“This capacity expansion is part of Klöckner Pentaplast’s long-term strategy to leverage our global footprint to maximize improvements across the value chain, with a focus on being even more responsive to our pharmaceutical customers’ needs now and in the future,“ says Markus Pischulti, Business Director, Pharmaceutical Films EMEA.

About Klöckner Pentaplast Group

The Klöckner Pentaplast Group is a global leader in providing packaging, printing and specialty solutions serving the pharmaceutical, medical device, food, beverage and card markets among others. With a broad portfolio of rigid plastic films and services powered by innovation, Klöckner Pentaplast plays an integral role in the customer value chain by marketing and protecting product integrity, safety, consumer health and ultimately, brand reputation.

Klöckner Pentaplast continuously earns high EcoVadis ratings, indicating the company’s commitment to Corporate Social Responsibility throughout its global operations. kp’s practices rank in the top 8% of suppliers within the respective industry classification of plastics manufacturing and in the top 12% of over twenty thousand suppliers evaluated by EcoVadis. In benchmark comparison within the plastics manufacturing industry, kp is ahead of the industry average in all four areas assessed: Environment, Labor Practices, Fair Business Practices, and Responsible & Sustainable Procurement. Klöckner Pentaplast is among the top 5% of suppliers assessed in industry classification for Environmental Practices and in the top 9% of suppliers assessed in respective industry classification of Fair Business Practices. Visit www.kpfilms.com.
phone 01132 540 711
email enquiries@kloeckner.com
web www.kloecknermetalsuk.com/
email Kloeckner Metals UK, Valley Farm Road, Stourton, Leeds, LS10 1SD, UK
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Avacta and Mologic Enter Research and Product Development Collaboration Agreement

Avacta announces the formation of a collaborative research partnership
More info >>


White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement